Navigation Links
Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
Date:5/5/2011

ndocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease. The safety and effectiveness of Afinitor in the treatment of patients with carcinoid tumors have not been established.

For more information visit www.AFINITOR.com/pNET or call 1-888-4-AFINITOR. US patients who may be eligible for financial assistance can learn about the Patient Assistance Now Oncology (PANO) reimbursement support program by contacting 1-800-282-7630 or visiting the Afinitor website.

Afinitor is approved in the US for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib and in the European Union (EU) for the treatment of patients with advanced RCC whose disease has progressed on or after treatment with vascular endothelial growth factor (VEGF)-targeted therapy.

Afinitor is also approved in the US to treat patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis who require therapeutic intervention but are not candidates for curative surgical resection. The effectiveness of Afinitor is based on an analysis of change in SEGA volume. Clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been shown. Novartis has submitted marketing applications for everolimus for this use to the European Medicines Agency (EMA) and the Swiss Agency for Therapeutic Products (Swissmedic), and additional regulatory submissions are under way worldwide.

Afinitor is available in the US in 2.5 mg, 5 mg and 10 mg tablet strengths.

In the US, everolimus is available in different dosage strengths for the non-oncology patient population under the trade name Zortress® for the prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a kidney transplant. In the EU, everolimus is available in different
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
2. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
3. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
4. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
5. Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients
6. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
7. Final Approval of Novartis Gender Discrimination Settlement Slated for November 19
8. Study in NEJM Shows Novartis Drug Afinitor® Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
9. VIDEO from thenewsmarket.com and Novartis: Novartis drug Afinitor® Approved by FDA as First Medication for Children and Adults With a Benign Brain Tumor Associated With Tuberous Sclerosis
10. Novartis to Expand Global Research Headquarters in Cambridge, MA
11. VIDEO From thenewsmarket.com and Novartis: Phase III Data Show That Novartis Meningococcal Vaccine Menveo® Demonstrated Robust Immunogenicity in Infants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... and VIENNA , July 31, ... a press conference in New York ... a vaccine against Parkinson,s disease. PD01A is the first therapy ... enter clinical testing. The Michael J. Fox Foundation ... 1.5 million grant, and presented at the press conference on ...
(Date:7/31/2014)... and LONDON , July 31, 2014 /PRNewswire/ ... services provider for the medical industries, announced today the incorporation of ... United Kingdom has one of the largest ... 8.9 billion in 2012 and it is projected to increase by ... USD 234 billion in 2012, equal to 9.5% of GDP. Despite ...
(Date:7/31/2014)... Texas , July 31, 2014 Vermillion, Inc. ... and women,s health, will hold a conference call on Thursday, ... results for the second quarter ended June 30, 2014. Financial ... the call. Vermillion,s Chairman, President and CEO ... question and answer period. Date: Thursday, August 14, ...
Breaking Medicine Technology:First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4genae Opens Offices in London 2Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2
... HOFFMAN ESTATES, Ill., Jan. 24, 2012 Life Spine, a ... for the surgical treatment of spinal disorders, announced record revenues ... introductions in 2011. The record revenue reflects ... 2011. "This has been an outstanding year for Life Spine. ...
... 2012  LoneStar Heart Inc., based here, today announced that ... Maciejewski to the company,s board of directors. The new ... for LoneStar Heart; Frank Ahmann, the company,s president and ... of Vessix Vascular, Inc.; and Eric N. Olson, Ph.D., ...
Cached Medicine Technology:LoneStar Heart Inc. Names Andrew J. Coats, M.D., and Mark Maciejewski to Its Board of Directors 2LoneStar Heart Inc. Names Andrew J. Coats, M.D., and Mark Maciejewski to Its Board of Directors 3
(Date:7/31/2014)... Miami, FL (PRWEB) July 31, 2014 ... (LMS) which continues to help healthcare agencies to ... help companies and agencies meet their accreditation ... with competency based training. , Healthcare administrators ... a few clicks of the mouse. Courses can ...
(Date:7/31/2014)... FL (PRWEB) July 31, 2014 Zensah®, ... released their innovative compression elbow sleeve , designed ... elbow pain, in two new bright colors for summer. ... pink and blue. Made of innovative proprietary Zensah® fabric, ... wicking and odor-preventing fabric. It features a no-slip cuff ...
(Date:7/31/2014)... 31, 2014 To further educate the ... provide the following safety information regarding leaving children in ... can have deadly consequences. Because a child’s body can ... of adults, leaving children alone in a hot vehicle ... even death. , Statistics of Children Left Alone in ...
(Date:7/31/2014)... 2014 Most mommy blogs are simple ... purpose is to attract all mothers from all walks ... particular group; whether its high fashion or child rearing. ... everything on the Internet was so segmented. “I found ... particular topic and then search Google to get information ...
(Date:7/31/2014)... A chance meeting at last April’s ... country artist/writer-producer Jimmy Robbins to Etymotic Research and ... an innovator in hearing wellness solutions, and maker ... 2012, Etymotic’s Music•PRO® Electronic Earplugs have revolutionized hearing ... and restoring natural hearing when hearing is not ...
Breaking Medicine News(10 mins):Health News:Company Helps Healthcare Agencies to Pass Inspections and Audits 2Health News:Company Helps Healthcare Agencies to Pass Inspections and Audits 3Health News:Compression Elbow Sleeve Provides Relief From Elbow Pain to Golfers and Tennis Players 2Health News:Compression Elbow Sleeve Provides Relief From Elbow Pain to Golfers and Tennis Players 3Health News:The Rothenberg Law Firm LLP Teams Up with Local Philadelphia TV Stations to Promote Awareness of the Dangers of Leaving Children Unattended in a Hot Vehicle 2Health News:The Rothenberg Law Firm LLP Teams Up with Local Philadelphia TV Stations to Promote Awareness of the Dangers of Leaving Children Unattended in a Hot Vehicle 3Health News:Mommylish Launches Its Website 2Health News:Country Star Jimmy Robbins Now Using Etymotic’s MusicPRO Electronic Earplugs 2
... ultrasound and specially modified contrast agents may allow researchers ... to research published in the March issue of The ... The technique enables researchers to visualize tumor activity at ... be helpful for the early detection of disease," said ...
... If the behavior of the seasonal form of the ... are good that most strains of the pandemic H1N1 flu ... for use against it. Researchers at Ohio State University ... virus, which first infected humans during the 1918 pandemic. It ...
... ... beef sold at checkout could help save lives when E. coli outbreaks happen because ... identify the products that are making people sick in order to bring outbreaks under ... ...
... ... has launched an improved web viewer for its flagship Evercore® – Clinical Enterprise Suite ... of the size of the facility. , ... Milwaukee, WI (PRWEB) March 1, 2010 -- TeraMedica Healthcare Technology, ...
... ... in Pharma, Health and Wellness. , ... Philadelphia, PA (PRWEB) March 1, 2010 -- Acknowledging more than 13 ... for specialization, Razorfish has launched Razorfish Health , a dedicated health and wellness ...
... ... ... ... ...
Cached Medicine News:Health News:The proof's in the bubbles 2Health News:Pandemic flu, like seasonal H1N1, shows signs of resisting Tamiflu 2Health News:Pandemic flu, like seasonal H1N1, shows signs of resisting Tamiflu 3Health News:Pandemic flu, like seasonal H1N1, shows signs of resisting Tamiflu 4Health News:Food Safety Attorney Fred Pritzker Calls on Food Retailers to Keep Precise Beef Handling Records 2Health News:Food Safety Attorney Fred Pritzker Calls on Food Retailers to Keep Precise Beef Handling Records 3Health News:TeraMedica Unveils Improved Univision, Now Offering a Multi-Layer Enterprise Viewing Platform 2Health News:Razorfish Launches Independent Dedicated Health Brand 2Health News:Razorfish Launches Independent Dedicated Health Brand 3Health News:Razorfish Launches Independent Dedicated Health Brand 4Health News:California to Examine Health Impacts of Landmark Cap-and-Trade Program 2Health News:California to Examine Health Impacts of Landmark Cap-and-Trade Program 3Health News:California to Examine Health Impacts of Landmark Cap-and-Trade Program 4Health News:California to Examine Health Impacts of Landmark Cap-and-Trade Program 5
... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
... are constructed of a patented ... polyvinyl acetal sponge. Each device ... to both surgeon and patient, ... firm enough to gently manipulate ...
... Products provide the surgeon ... products for unparalleled fluid ... of fine microsurgical instruments. ... is highly absorbent, fast ...
... KeraCel Ophthalmic Products are ... formulation of lint-free MEROCEL polyvinyl ... configured to be beneficial to ... being absorbent, and yet firm ...
Medicine Products: